<DOC>
	<DOCNO>NCT00003021</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness bizelesin treat patient advanced cancer .</brief_summary>
	<brief_title>Bizelesin Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose bizelesin patient advance cancer . II . Determine qualitative quantitative toxic effect therapy patient . III . Determine pharmacokinetics therapy patient . IV . Determine recommend dose drug phase II trial . V. Determine antitumor effect therapy patient . OUTLINE : This dose-escalation study . Patients receive bizelesin IV day 1 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bizelesin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Bizelesin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor therapeutic option potentially curative demonstrated increase survival No primary metastatic CNS malignancy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin normal SGOT great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No atrial ventricular arrhythmia require medication No ischemic event within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No active malignancy except curatively treat carcinoma situ cervix basal cell skin cancer No serious concurrent medical illness No history seizure disorder require active therapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 10 % bone marrow No prior electronbeam radiotherapy At least 4 week since prior radiotherapy Surgery : Prior surgery allow Other : Recovered prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>